Long-term COVID has been linked to stress, depression and cognitive impairment.

Published Date: 13 Mar 2023

Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...

Read Full News

Latest News

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Latest News

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

News All Time

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Repetitive TMS Boosts Quality of Life in Younger, Older Adults with Depression Chelsie Derman

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Rethinking Addiction Recovery: From Symptoms to Systems

Rethinking Addiction Recovery: From Symptoms to Systems

Comorbid Anxiety Lowers Accelerated Theta Burst Response in Depression Chelsie Derman

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Non-Invasive Vagus Nerve Stimulation Boosts Food Liking in Depression Chelsie Derman

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

6 Psychiatry Headlines You Missed in October 2025

6 Psychiatry Headlines You Missed in October 2025

Psychedelics might help terminal patients find peace

In clinical trials around the world, a surprising treatment is showing promise for people with terminal illnesses: psychedelic therapy.

Tracing schizophrenia's origins: Study maps chromatin accessibility in postmortem brain tissue

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world (i.e., delusions), and other disruptions in thought, emotion and perception. Recent genetic studies ...

Not all PTSD therapies keep veterans in treatment, study warns

About a quarter of U.S. service members and veterans who start psychotherapy for post-traumatic stress disorder quit before they finish treatment. But not all therapies are equal in their appeal, with some effective approaches ...

Inequalities in mental health compulsory admissions worsened during the pandemic, UK study finds

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and South London and Maudsley NHS Foundation Trust has shown striking inequalities between ethnic groups in the rate of involuntary admissions ...

Recommended News For You

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

A novel blood test may enable the early identification of common, fatal cancers.

Study links persistent fatigue in breast cancer survivors to increased inflammation

examining differences in the rates of breast reconstruction following mastectomies.

Recommended Articles For You

Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment 

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

A Closer Look at the Effects of Sickle Cell on Eyesight 

The Journey Beyond Treatment: Empowering Cancer Survivorship with Technology and Artificial Intelligence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

2.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

3.

More People Than Previously Believed Have Schizophrenia.

4.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

5.

Is Laughter Good for Blood Glucose Control?

1.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

2.

Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support

3.

Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide

4.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

5.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

3.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot